Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma
- PMID: 16951268
Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma
Erratum in
- Ann Clin Lab Sci. 2006 Autumn;36(4):442. Riefkohl, Waldemar [added]
Abstract
Head and neck squamous cell carcinoma (HNSCC) has a relatively high mortality rate and poor prognosis. Recently, we showed that overexpression of phosphorylated (p) nuclear factor-kappaB (NF-kappaB) in squamous cell carcinoma of the tonsil (SCCT) and high grade dysplasia is associated with a poor prognosis. Because the mammalian target of the rapamycin (mTOR) pathway contributes to the activation of NF-kappaB through immunophilin/mTOR signaling, we investigated: (a) the immunohistochemical expression and state of activation and potential clinical significance of components of the mTOR signal transduction pathway in SCCT patients (morphoproteomics); and (b) the inhibitory effects of rapamycin on the growth and state of activation of mTOR in 2 HNSCC cell lines (pharmacoproteomics). Archival biopsy materials from 39 patients with SCCT were studied by immunohistochemistry for the expression of p-mTOR (Ser 2448), and p-p70S6K (Thr 389), and/or cyclin D1. Results for SCCT were compared with adjacent non-neoplastic epithelium, when present, and with normal tonsillar epithelium from approximately age-matched controls; clinical outcomes were also assessed. SCCT showed mTOR (Ser 2448) expression in 93% (30/32 cases) with 2+ or 3+ plasmalemmal and/or cytoplasmic intensity in 84% vs 42% in surface epithelium from normal tonsils (p <0.001). The mean combined expression score (signal intensity x percentage of positive cells) for p-p70S6K was significantly greater in the SCCT group vs adjacent non-neoplastic squamous epithelium and normal tonsillar epithelium of the control group (p <0.05). A relationship existed between higher p-p70S6K expression levels in the non-neoplastic squamous epithelium adjacent to the SCCT and increased risk of death from disease (hazard ratio = 7.9; 95% confidence interval (CI) = 2.1 to 29.9; p = 0.002). There was also a relationship between nuclear expression of cyclin D1 in SCCT and shortened recurrence-free survival (p = 0.015). Two human HNSCC cell lines, SCC-15 and FaDu, were incubated with and without rapamycin to assess its impact on growth and on the expression of p-mTOR. Rapamycin in a dose-dependent fashion inhibited growth more in SCC-15, which correlated with a greater reduction in constitutively activated p-mTOR (Ser 2448) as shown by Western blotting. In conclusion, these morphoproteomic and pharmacoproteomic data collectively provide a rationale for selecting mTOR effectors as therapeutic targets in HNSCC.
Similar articles
-
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.Ann Clin Lab Sci. 2008 Summer;38(3):195-209. Ann Clin Lab Sci. 2008. PMID: 18715846
-
Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.Ann Clin Lab Sci. 2006 Summer;36(3):283-93. Ann Clin Lab Sci. 2006. PMID: 16951269
-
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.Cancer Res. 2005 Nov 1;65(21):9953-61. doi: 10.1158/0008-5472.CAN-05-0921. Cancer Res. 2005. PMID: 16267020
-
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].Bull Cancer. 2006 Nov;93(11):1139-43. Bull Cancer. 2006. PMID: 17145584 Review. French.
-
Mammalian target of rapamycin and head and neck squamous cell carcinoma.Head Neck Oncol. 2011 Apr 24;3:22. doi: 10.1186/1758-3284-3-22. Head Neck Oncol. 2011. PMID: 21513566 Free PMC article. Review.
Cited by
-
Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer.Int J Clin Exp Pathol. 2008 Jan 1;1(4):333-42. Int J Clin Exp Pathol. 2008. PMID: 18787612 Free PMC article.
-
Genomics and advances towards precision medicine for head and neck squamous cell carcinoma.Laryngoscope Investig Otolaryngol. 2017 Aug 22;2(5):310-319. doi: 10.1002/lio2.86. eCollection 2017 Oct. Laryngoscope Investig Otolaryngol. 2017. PMID: 29094075 Free PMC article. Review.
-
Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.Laryngoscope. 2010 Jun;120(6):1159-65. doi: 10.1002/lary.20917. Laryngoscope. 2010. PMID: 20513033 Free PMC article.
-
REDESIGN: RDF-based Differential Signaling Framework for Precision Medicine Analytics.AMIA Jt Summits Transl Sci Proc. 2018 May 18;2017:35-44. eCollection 2018. AMIA Jt Summits Transl Sci Proc. 2018. PMID: 29888036 Free PMC article.
-
Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.Int J Clin Exp Pathol. 2010 Jan 28;4(2):134-46. Int J Clin Exp Pathol. 2010. PMID: 21326806 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous